69 Health Tech Startups in Cambridge to Watch in 2024
How do we build this list?
Tracking:
Last update to the database: April 9, 2024. See changelog.
Join 23,000+ founders, operators and investors.
Seedtable Score Learn how we calculate it here
We use raw data and human intuition to understand if a company is likely to outsource services like Hiring, Design, Development, etc.
company | score | funding | investors | employees | industries | biz model | city | contact |
---|---|---|---|---|---|---|---|---|
Drug delivery platform. |
$24M · Series A | 4BIO Capital, UCB Ventures, Business Growth Fund | 1 to 10 | Health Tech, Biotech | Cambridge, UK | •••••••••••@vianautis.com | ||
AI platform to advance precision medicine clinical trials. |
$11M · Series A | Seedcamp, Plural, Episode 1 | 11 to 50 | Health Tech, Biotech | B2B, SaaS | Cambridge, UK | •••••••••••@sanogenetics.com | |
Surgical robotic system for minimal access surgery. |
$164M · Series D | SoftBank Group, Tencent, ABB Technology Ventures | 501 to 1000 | Health Tech, Robotics | B2B | Cambridge, UK | •••••••••••@cmrsurgical.com | |
Small molecule neoantigen immuno-oncology therapies developer. |
$12M · Series B | Sixth Element Capital, 3B Future Health Fund, Astellas Venture Management | 1 to 10 | Health Tech | Cambridge, UK | •••••••••••@neophore.com | ||
Transforming mental healthcare by unlocking the power of clinical data |
$52M · Series B | Molten Ventures | 101 to 250 | Health Tech, Deep Tech | B2B, B2C | Cambridge, UK | •••••••••••@iesogroup.com | |
Physiological upregulation therapy to treat neurodegenerative diseases. |
$5M · Seed | SV Health Investors | 11 to 50 | Health Tech, Biotech | Cambridge, UK | •••••••••••@harnesstx.com | ||
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. |
$66M | Seventure Partners, Cambridge Innovation Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Manufacturing | B2B | Cambridge, UK | •••••••••••@microbiotica.com | |
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases. |
$56M · Series B | Balderton Capital, Atomico, Amadeus Capital | 51 to 100 | Health Tech, AI, Biotech, Pharma, Data and Analytics, Business Intelligence | B2B, SaaS | Cambridge, UK | •••••••••••@healx.io | |
Metrion Biosciences is a Contract Research Organization. |
$4M · Series A | Gresham House Ventures, NPIF Maven Equity Finance | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@metrionbiosciences.com | ||
Endomag is a medical technology company devoted to improving breast cancer care through its magnetic sensing technologies. |
$20M · Series D | Molten Ventures | 51 to 100 | Health Tech, Hardware | B2B | Cambridge, UK | •••••••••••@endomag.com | |
Cancer diagnostics. |
$16M · Series A | Business Growth Fund | 51 to 100 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@cyted.ai | ||
Genomics company building safer cell and gene therapies. |
$15M · Series A | Tencent, Illumina Ventures | 1 to 10 | Health Tech, Biotech | Cambridge, UK | •••••••••••@brokenstringbio.com | ||
AI-driven tech for respiratory conditions. |
$9M · Series A | Business Growth Fund, Downing Ventures | 11 to 50 | Health Tech, AI | Cambridge, UK | •••••••••••@tidalsense.com | ||
Supplant is a biotechnology platform that makes sugar substitutes. |
$24M | Khosla Ventures, Felicis Ventures, Y Combinator | 11 to 50 | Health Tech, Foodtech, Deep Tech, Manufacturing | B2B | Cambridge, UK | •••••••••••@supplant.com | |
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. |
$41M · Series A | Metaplanet Holdings, BlueYard Capital | 101 to 250 | Health Tech, Biotech, Deep Tech, Business Intelligence | B2B | Cambridge, UK | •••••••••••@bit.bio | |
Mogrify® will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies. |
$10M · Series A | Astellas Venture Management, Ahren Innovation Capital, Parkwalk Advisors | 101 to 250 | Health Tech, Biotech, Deep Tech | B2B | Cambridge, UK | •••••••••••@mogrify.co.uk | |
Precision software for surgeries. |
$11M · Series A | Pembroke VCT | 11 to 50 | Health Tech | B2B, SaaS | Cambridge, UK | •••••••••••@cydarmedical.com | |
Drug manufacturer. |
$10M · Series A | Biospring Partners | 501 to 1000 | Health Tech, Biotech, Pharma | B2B, SaaS | Cambridge, UK | •••••••••••@abzena.com | |
Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers. |
$5M | Calculus Capital | 11 to 50 | Health Tech, Biotech, Pharma, Business Intelligence | B2B | Cambridge, UK | •••••••••••@axolbio.com | |
Cake is the world's largest platform for helping people navigate end-of-life. |
$14M | Creandum, Headline | 1 to 10 | Health Tech, Mobile, Mobility & Transportation, Manufacturing, Sales and Marketing | B2C | Cambridge, UK | •••••••••••@joincake.com | |
Eagle Genomics is a enterprise software solutions company to enable the management, orchestration and exploitation of life sciences data. |
$3M · Seed | ETF Partners, Granpool Innovative Investments | 11 to 50 | Health Tech, Biotech | B2B | Cambridge, UK | •••••••••••@eaglegenomics.com | |
Epitopea is a transatlantic cancer immunotherapeutics company. |
$13M · Seed | Cambridge Innovation Capital | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Cambridge, UK | •••••••••••@epitopea.com | |
Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology. |
$11M · Seed | GV, Forbion Capital Partners | 1 to 10 | Health Tech, Biotech, Deep Tech, Manufacturing | B2B | Cambridge, UK | •••••••••••@mestagtx.com | |
Deubiquitylating enzyme (DUB) drug discovery and development platform. |
$6M · Series A | Sofinnova Partners, Rosetta Capital, Pfizer Venture Investments | 51 to 100 | Health Tech, Biotech | Cambridge, UK | •••••••••••@missiontherapeutics.com | ||
PetMedix is a pet therapeutics startup. |
$13M · Series A | Cambridge Innovation Capital, Parkwalk Advisors | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Cambridge, UK | •••••••••••@petmedix.co.uk | |
PillSorted is a Pharmacy, blending compassionate care and innovative technology to deliver a truly Personal Pharmacy service. |
$6M · Seed | Hoxton Ventures | 11 to 50 | Health Tech, CPG & Consumer Goods, Pharma, Ecommerce | B2B, B2C, SaaS | Cambridge, UK | •••••••••••@pillsorted.com | |
Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw. |
$88M · Series D | 51 to 100 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@cambridge-epigenetix.com | |||
Artios Pharma is a independent DNA Damage Response company with a strong pipeline of novel cancer therapies. |
$152M · Series C | 101 to 250 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@artiospharma.com | |||
Owlstone Medical is a diagnostics company that developed a non-invasive breathalyzer for infectious disease detection. |
$57M · Series D | 101 to 250 | Health Tech | Cambridge, UK | •••••••••••@owlstonemedical.com | |||
Sphere Fluidics develops products for use in single cell analysis and characterization, and provides associated collaborative R&D services. |
$4M | Sofinnova Partners | 11 to 50 | Health Tech, Deep Tech | B2B | Cambridge, UK | •••••••••••@spherefluidics.com | |
Semarion leverages microfabrication technology to build smart materials and develop novel cell assaying applications. |
$2M · Seed | Parkwalk Advisors, Martlet Capital | 1 to 10 | Health Tech, Biotech, Manufacturing | B2B | Cambridge, UK | •••••••••••@semarion.com | |
PhoreMost is a new-model drug discovery company based in Cambridge, UK. |
$45M · Series B | 1 to 10 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@phoremost.com | |||
Novel cancer therapies. |
$30M · Series B | 11 to 50 | Health Tech, Deep Tech | B2C | Cambridge, UK | •••••••••••@stormtherapeutics.com | ||
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases. |
$16M | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@wrentherapeutics.com | |||
Transforming the way a nation delivers its healthcare to its population, from prescriptions to personalised services. |
$604k | Innovate UK | 11 to 50 | Health Tech | Cambridge, UK | •••••••••••@healthera.co.uk | ||
Clinical stage studies to discover biomarkers to improve medical diagnosis. |
$2M · Seed | 1 to 10 | Health Tech, Biotech | Cambridge, UK | •••••••••••@upfrontdiagnostics.com | |||
Charco Neurotech is a medical technology company that develops non-invasive wearable devices. |
$692k · Pre Seed | Amadeus Capital, Parkwalk Advisors | 11 to 50 | Health Tech, Hardware, Biotech, Manufacturing | B2B | Cambridge, UK | •••••••••••@charconeurotech.com | |
CardiaTec is a digital biotechnology venture combining the power of AI and expert talent to redesign cardiovascular drug discovery. |
$1M · Pre Seed | 1 to 10 | Health Tech, AI, Biotech, Deep Tech, Pharma | B2B | Cambridge, UK | •••••••••••@cardiatec.ai | ||
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function. |
$18M | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Cambridge, UK | •••••••••••@nrgtherapeutics.com | ||
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance. |
$9M | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@phicotx.co.uk | |||
Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis. |
$7M · Series A | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@predictimmune.com | |||
PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders. |
$1M | Parkwalk Advisors, Martlet Capital | 11 to 50 | Health Tech, Biotech, Data and Analytics | B2B, SaaS | Cambridge, UK | •••••••••••@psyomics.com | |
Qureight is an imaging analytics company. |
$637k · Seed | Ascension Ventures, Playfair Capital, CMS Ventures | 1 to 10 | Health Tech, Machine Learning, Data and Analytics | B2B, SaaS | Cambridge, UK | •••••••••••@qureight.com | |
Treatment for patients with chronic wounds. |
$13M · Series B | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@solascure.com | |||
Spotta is a provider of smart pest systems. |
$1M · Seed | Martlet Capital | 1 to 10 | Health Tech, Manufacturing, Community & Lifestyle | B2C | Cambridge, UK | •••••••••••@spotta.co | |
Genomic technology developer to detect biomarkers for non-small cell lung cancer (NSCLC). |
$940k · Seed | Octopus Ventures, Longwall Venture, BlueYard Capital | 11 to 50 | Health Tech, Biotech | B2B | Cambridge, UK | •••••••••••@biofidelity.com | |
Transine Therapeutics is a developer of a platform for physiological upregulation of proteins using targeted translation enhancers, SINEUPs. |
$12M · Seed | 11 to 50 | Health Tech, Biotech, Deep Tech | B2B | Cambridge, UK | •••••••••••@transinetx.com | ||
PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery. |
$2M · Seed | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma, Business Intelligence | B2B, SaaS | Cambridge, UK | •••••••••••@pharmenable.com | ||
Spirea Ltd. operates as a healthcare technology company. |
$2M | Health Tech | Cambridge, UK | •••••••••••@spirea.co.uk | ||||
Monocl empowers life science professionals with the complete global expert solution for impactful outreach and strategic engagement. |
$3M | 51 to 100 | Health Tech, Biotech, Deep Tech, Pharma, Business Intelligence | B2B, SaaS | Cambridge, UK | •••••••••••@monocl.com | ||
Congenica is a biotechnology company that provides a diagnostic decision support platform. |
N/A | Cambridge Innovation Capital, Parkwalk Advisors, QVentures | 11 to 50 | Health Tech, Biotech, Genetics | B2B | Cambridge, UK | •••••••••••@congenica.com | |
AI extracting health data from sound. |
$585k · Pre Seed | 1 to 10 | Health Tech, Hardware, AI, Machine Learning, Manufacturing | B2B | Cambridge, UK | •••••••••••@decorte.co.uk | ||
52 North Health is developing a fully-integrated clinical, AI-driven medical device-based system called NeutroCheck for people with cancer. |
$1M · Seed | 1 to 10 | Health Tech, Hardware, AI, Manufacturing | B2B | Cambridge, UK | •••••••••••@52north.health | ||
Legacy is a digital fertility clinic for men, founded at Harvard & backed by Y Combinator, FirstMark Capital, Bain Capital and celebrities. |
N/A | 101 to 250 | Health Tech, Biotech, Proptech & Real Estate, Femtech, Mobile, Energy & Nuclear, Genetics, Business Intelligence, Fertility | B2B, SaaS | Cambridge, UK | •••••••••••@givelegacy.com | ||
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment. |
N/A | 1 to 10 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@polyprox.com | |||
Exonate is a biotech company spun out of the University of Nottingham that is focused on alternative splicing of (VEGF) in ophthalmology. |
N/A | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@exonate.com | |||
Definigen provides human cells to the drug discovery sector for use in lead optimization and toxicity programs. |
N/A | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@definigen.com | |||
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing. |
N/A | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@revolobio.com | |||
Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated. |
N/A | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@ccg.ai | |||
Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health. |
N/A | 251 to 500 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@horizondiscovery.com | |||
Z Factor Limited is a drug discovery company to identify and develop therapeutic agents to treat alpha-1-antitrypsin deficiency |
N/A | Health Tech, Publishing | Cambridge, UK | •••••••••••@zfactor.co.uk | ||||
CS Genetics develops new technology for genomics, based on scientific insights and conceptual innovations in NGS techniques. |
N/A | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@csgenetics.com | |||
Produce pure, mature and highly consistent batches of human cell types for research, toxicology and drug development. |
N/A | 11 to 50 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@elpis.ltd | |||
F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology. |
N/A | 51 to 100 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@f-star.com | |||
MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins |
N/A | 1 to 10 | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@morphogen-ix.com | |||
Mursla is a quantum biology diagnostics company. |
N/A | 11 to 50 | Health Tech | Cambridge, UK | •••••••••••@mursla.com | |||
Nemesis Bioscience is a new biopharmaceutical company . |
N/A | Health Tech, Deep Tech | Cambridge, UK | •••••••••••@nemesisbio.com | ||||
Lab 21 supports healthcare providers and the pharmaceutical and biotechnology industries with technically advanced testing services. |
N/A | 51 to 100 | Health Tech | Cambridge, UK | •••••••••••@lab21.com | |||
Kirontech uses cutting edge machine learning technology to revolutionize the use of healthcare data. |
N/A | 11 to 50 | Health Tech, Data and Analytics | Cambridge, UK | •••••••••••@kirontech.com |
Sign up to access our full database
Enter your email and get access to 17,000+ technology companies you can partner with.